Search

Displaying results 3961 - 3970 of 8698 in total
  1. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    ApprovedInvestigational

    to provide passive immunization against RSV infection as an alternative means of protection. … [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233]

  2. Drug

    PZ-128

    go.drugbank.com/drugs/DB11839
    Investigational

    PZ-128 has been used in trials studying the prevention and treatment of Heart Diseases, Coronary Disease, Arteriosclerosis, Vascular Diseases, and Myocardial Ischemia, among others.

  3. Drug

    HKI-357

    go.drugbank.com/drugs/DB13002
    Investigational

    Hki 357 is under investigation in clinical trial NCT00550381 (Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy Subjects).

  4. Drug

    Cadonilimab

    go.drugbank.com/drugs/DB16680
    Investigational

    Cadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).

  5. Drug

    NS-3728

    go.drugbank.com/drugs/DB05835
    Experimental

    NS3728 is an orally active chloride channel blocker for the treatment of cancer.

  6. Drug

    Etravirine

    go.drugbank.com/drugs/DB06414
    ApprovedInvestigational

    Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). … Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    IDM-2

    go.drugbank.com/drugs/DB05293
    Experimental

    IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. … IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.

  8. Drug

    Hydroflumethiazide

    go.drugbank.com/drugs/DB00774
    ApprovedWithdrawn

    A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)

  9. Drug

    Brepocitinib

    go.drugbank.com/drugs/DB15003
    ApprovedInvestigational

    [L64097] The FDA approved brepocitinib on August 27, 2026 for the treatment of dermatomyositis in adult patients, making it the first targeted oral therapy approved for the condition.[L64115] … Brepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  10. Drug

    RO7284755

    go.drugbank.com/drugs/DB17527
    Investigational

    RO7284755 is an investigational cancer drug: it is a PD-1-targeted IL-2 variant antibody fusion protein.